Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

DOI Web Site Web Site 7 Citations

Journal

  • The Lancet

    The Lancet 396 (10265), 1817-1828, 2020-12

    Elsevier BV

Citations (7)*help

See more

Report a problem

Back to top